NovaBridge Biosciences has enrolled the first patient in a global Phase 2 study evaluating givastomig in combination with nivolumab and chemotherapy for HER2-negative, first-line metastatic gastric cancer, with top-line results expected in 2027.
Antibody-drug conjugates targeting TROP2 with topoisomerase I inhibitor payloads are currently marketed in breast and lung cancer, with over 100 such ADCs now in clinical trials for various malignancies including gastrointestinal tumors.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07104175 |
Predictive Value of NRS2002 and GLIM for Complications After GI Malignancy Surgery |
COMPLETED | |
| NCT06644274 |
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Gastrointestinal Malignancies |
RECRUITING | |
| NCT05229588 |
Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations |
COMPLETED | PHASE2 |
| NCT03749083 |
A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation After Clinical Complete Response to Neoadjuvant Therapy for Rectal Cancer |
WITHDRAWN |
